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Adult  congenital  heart  disease  is  one  of  the  most  important  clinical  issues  not  only  for  pediatric  cardiol-
ogists  but  also  adult  cardiologists.  After  the introduction  of  catheter  intervention  for atrial  septal  defect
in the pediatric  population,  therapeutic  advantages  of  this  less  invasive  procedure  now  focused  on even
geriatric patients.  The  most  valuable  clinical  beneﬁt  of  this  procedure  is  the signiﬁcant  improvement  in
symptoms  and  daily  activities,  which  result  from  the  closure  of  left to  right  shunt  without  thoracotomy
or  cardiopulmonary  bypass  surgery.  Although  currently  available  therapeutic  options  for  device  closure
for congenital  heart  disease  in  Japan  are  limited  to atrial septal  defect,  patent  ductus  arteriosus,  or  some
vascular  abnormalities  such  as  coronary  arteriovenous  ﬁstula,  various  new  techniques  or  devices  such
as ventricular  septal  defect  device,  pulmonary  valve  implantation,  are  going  to  be  introduced  in  the  near
future. To  perform  safely  and  achieve  good  procedure  success,  real  time  imaging  plays  an  important  role  in
interventional  procedures.  Real  time  three-dimensional  transesophageal  echocardiography  can provide
high quality  imaging  for  anatomical  evaluation  including  defect  size,  surrounding  rim  morphology,  and
the relationship  between  device  and  septal  rim. In adult  patients,  optimal  management  of comorbidities
is  an  important  issue,  including  cardiac  function,  arrhythmias,  pulmonary  function,  and  renal  function.
In  particular,  atrial  arrhythmias  are  key  issues  for long-term  outcome.  Because  the  interventional  proce-
dures are  not  complication-free  techniques,  the  establishment  of a surgical  back-up  system  is  essential
for achieving  a safe  procedure.  Finally,  the establishment  of  a  team  approach  including  pediatric  and  adult
cardiologists,  cardiac  surgeons,  and  anesthesiologists  is  the  most  important  factor  for  a good  therapeutic
outcome.  Their  roles  include  pre-interventional  hemodynamic  evaluation,  good  imaging  technique  for
anatomical  evaluation,  management  of  comorbidities,  and surgical  back  up.
© 2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
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dult congenital heart disease and catheter intervention
A remarkable improvement in the survival of patients with con-
enital heart disease (CHD) has occurred over the past 50 years
ince reparative surgery has become commonplace. In Japan, it is
stimated that there are at least 400,000 adult CHD patients; this
umber is expected to increase by approximately 9000 patients
nnually [1–3]. Management of these patients is going to become
 critical issue even in our daily practice.
On the other hand, some patients with CHD have grown up
o adult age without signiﬁcant symptoms. These include those
ith atrial septal defect (ASD), patent ductus arteriosus (PDA), and
mall ventricular septal defect (VSD). However, such stable or less
ymptomatic conditions do not persist for life. Fig. 1 shows the mor-
ality of adult patients whose age over 60 years gradually increased
ver the past few decades [4].  It is well known that the mortality
rom CHD dramatically decreased in the past few decades, however,
specially in adult patients with CHD, mortality has been increas-
ng. The main cause of this phenomenon is that elderly patients
ith ASD died [5,6]. Thus, optimal management of elderly patients
ith ASD is very important.
atural course of ASD
ASD accounts for 7% of all CHD. The most common ASD is
 secundum defect versus defects located in the septum pri-
um,  sinus venosus defects, or unroofed coronary sinus [7]. If left
ntreated, these defects may  result in right-sided heart failure,
rrhythmia, and pulmonary hypertension. Although surgical clo-
ure of ASDs is safe, effective, and time-tested, it still requires open
eart surgery and hospitalization [8].  The majority of these children
re asymptomatic and diagnosed by school physical examination,
eart murmurs are detected by primary care pediatricians, and
ardiac echocardiography screening in the newborn period. If the
efect is smaller than 6 mm,  spontaneous closure can be expected
uring the newborn to pediatric period [9].  The operation is sched-
led based on children’s body size, usually before the elementary
chool with low mortality.
Although the catheter closure of pediatric patients or young
dults with ASD has attracted research interest over the past
wo decades, that of the older ASD population has yet to be
Fig. 1. Mortality of congenital hgy 60 (2012) 151–159
characterized [10]. Extrapolation of studies on younger patients
is not appropriate in geriatric patients. First, older patients with
ASD acquire comorbid conditions such as arrhythmia, hyperten-
sion, respiratory distress, and kidney disease, that always have an
inﬂuence on their heart conditions [11]. Second, older ASD patients
may  have inherently superior resiliency, milder disease, or bal-
anced physiology in contrast to those not surviving to an advanced
age. Therefore, older or geriatric patients with ASD represent a
distinct population for which focused studies are needed.
Catheter intervention of ASD
Device closure of secundum ASD is associated with low com-
plication rates, short anesthetic times, and short hospitalizations
[12]. When conditions are favorable, transcatheter secundum ASD
closure has become the treatment of choice rather than surgery in
many institutions. Echocardiography, either intracardiac or trans-
esophageal (TEE), plays a signiﬁcant role in the guidance of these
procedures and in the assessment of the ﬁnal result. Research
efforts are ongoing to examine other imaging modalities, such as
magnetic resonance imaging, as a means of guiding transcatheter
ASD closure. In Japan, only the Amplatzer septal occluder (St. Jude
Medical, Plymouth, MN,  USA) is currently approved for secun-
dum ASD closure [13]. This device was approved after prospective
clinical trials in the USA comparing outcomes with traditional
surgical closure revealed favorable results [12]. Amplatzer septal
occluder is composed of a nitinol wire mesh encasing Dacron fab-
ric (Fig. 2). The device is available in a wide range of sizes (6–38 mm)
and features a left and right atrial disk connected by a self-
centering connecting waist. This device is suitable for all subtypes of
secundum ASD and has successfully closed defects as large as
38 mm in diameter. Before release from the delivery cable, the
device can be repositioned or removed easily. Several reports
describe successful closure of secundum ASD with deﬁciencies of
the inferior, posterior, and superior rims as well as coronary sinus
defect.Imaging modality for ASD closure
Two-dimensional (2D) and color Doppler transthoracic echocar-
diography (TTE) can demonstrate the presence of ASDs, chamber
eart disease in Japan [4].
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Fig. 3. Assessment of surrounding rims using two-dimensional transesophageal
echocardiography (2D TEE). Surrounding tissue rims and atrial septal defect (ASD)
diameter should be measured in the phase of ventricular end systole with multiple
cross-sectional TEE plane. Distances from ASD to aorta (superoanterior rim; 2D TEE
view at 0–30◦), superior vena cava (superoposterior rim; 2D TEE view at 90–120◦),
right upper pulmonary vein (posterior rim; 2D TEE view at 110–120◦), inferior vena
◦
Coronary sinus septal defect is a rare type, in which a communica-Fig. 2. Amplatzer septal occluder.
ilatation, estimated pulmonary artery pressure, shunt ratio, and
ther coexisting heart disease with high sensitivity and speciﬁcity
n real time. And the advent of tissue Doppler imaging could facili-
ate understanding of cardiac diastolic function in which impaired
ardiac function before ASD closure may  lead to development of
ongestive heart failure after ASD closure especially in elderly
atients [14,15]. However, in terms of accurate assessment of ASD
orphology including measurements of maximal diameter and
urrounding rims, 2D TTE has sometimes limited ability to visual-
ze ASDs in detail clearly, especially in adult patients, thus precise
valuation using TEE are necessary in most ASD patients (Fig. 3)
16,17].
Three-dimensional (3D) echocardiography provides better spa-
ial visualization and 3D TEE can delineate the 3D structure with
 high resolution image. As a result, 3D echocardiography offers
he ability to improve display and our understanding of complex
esions such as valvular and CHD [18,19]. In addition, although
D echocardiography was initially based on reconstructed image
rom serial 2D images, which required cumbersome acquisition and
ime-consuming ofﬂine analysis, recently real-time 3D echocar-
iography using matrix array transducer has been available in
TE as well as TEE. 3D TTE is a promising modality to provide
omprehensible en face image of ASD because of its non-
nvasiveness, low cost, portability, and wide availability. In terms
f patient selection for transcatheter ASD closure, 3D TTE has
he potential to provide accurate information on ASD morphology
ncluding location, size, and surrounding rims for treatment both
n children and adults [20]. However, there are several limitations
f 3D TTE at present, such as dependence on the skill of the oper-
tor, restrictive echo window especially in elderly patients, echo
ropout in the region of the mid  portion which can lead to false
iagnoses of large defects, and lower both temporal and spatial
esolutions compared to 2D TTE. On the other hand, ASD morphol-
gy can be recognized with high-quality en face image using 3D
EE. Real time 3D TEE allows for evaluation of various shapes of
SD especially in patients with complex-shaped ASD like multiple
SDs (Fig. 4) [21,22].
Recently, we introduced intracardiac echocardiography (ICE) as
 new imaging modality. If ICE provides acceptable anatomicalcava (inferoposterior rim; 2D TEE view at 60–90 ), coronary sinus (2D TEE view at
100–120◦) and atrioventricular valve (inferoanterior rim; 2D TEE view at 135◦) are
assessed Ref. [16].
imaging, this procedure can be performed without general anes-
thesia (Fig. 5).
Patient selection for transcatheter ASD closure
Candidates for ASD closures have a hemodynamically signif-
icant atrial shunt or the presence of right ventricular volume
overload, and/or clinical symptoms of dyspnea, reduced exer-
cise capacity, or paradoxical embolism. Pulmonary vascular
resistance < 5 Wood units/m2 and peak pulmonary artery pres-
sure ≤ 70% of the systemic blood pressure are also important
conditions for ASD closure. In general, ASD with >10 mm in diam-
eter is considered to account for a signiﬁcant left-to-right shunt,
although ASD can enlarge with time independent of age at diag-
nosis and body surface area. In addition to these indications, ASD
morphology should be suited for transcatheter closure.
Morphological indication for transcatheter ASD closure
It is well known that morphological variations of ASD are fre-
quent and appropriate patient selection for transcatheter ASD
closure is crucial for successful procedures. ASDs are grouped into
four major categories: ostium primum; ostium secundum; sinus
venosus; and coronary sinus septal defect. Secundum defect is the
most common type of ASD in which the defect involves the region of
fossa ovalis, and this type is indicated for transcatheter ASD closure.tion occurs between the coronary sinus and the left atrium as a
result of unroofed coronary sinus. Primum septal defect and sinus
venosus are indicated for surgical repair. Regarding coronary sinus
154 T. Akagi / Journal of Cardiology 60 (2012) 151–159
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aig. 4. Various shape of atrial septal defect (ASD) visualized by three-dimensional
B)  Deﬁcient superoanterior rim. (C) Deﬁcient inferoposterior rim. (D) Deﬁcient bot
eptal defect, although surgical repair is the standard treatment for
his type of ASD, there are some case reports in which transcatheter
losure was successful [23].
In patients with secundum septal defect, two  crucial param-
ters, which are the maximal ASD diameter in order to select a
evice with the appropriate size and the surrounding rim dimen-
ions to optimize the placement of the device, should be assessed to
elect patients for transcatheter ASD closure. The defect must have
 maximal balloon sizing diameter less than 38 mm.  Most ASDs
ave an ellipsoidal shape and it varies during the cardiac cycle. The
ajor axis diameter of the defect measured in the phase of ventric-
lar end systole is mandatory for selecting the optimal device size
specially in patients undergoing the procedure without balloon
izing or multiple defects (Fig. 6). Transcatheter closure of large
SD with a maximal native diameter >25 mm is still challenging,
nd alternative special techniques for deployment of the device
re usually required. In regard to classiﬁcation of surrounding
ims, although there are some differences among studies, dis-
ances from ASD to aorta (superoanterior rim), superior vena cava
superoposterior rim), right upper pulmonary vein (posterior rim),
nferior vena cava (inferoposterior rim), coronary sinus and atri-
ventricular valve (inferoanterior rim) are assessed. The deﬁnition
f rim deﬁciency varies among different studies; any rim was
onsidered deﬁcient if its length is <5 mm.  In patients with
uperoanterior rim deﬁciency, a serious complication, so called car-
iac erosion, may  occur after device implantation. Although the
ccurate mechanisms of cardiac erosion are still not clear, oversizedsophageal echocardiography (3D TEE) (left atrial en face view). (A) Sufﬁcient rim.
eroanterior and inferoposterior rim.
devices (>150% of initial ASD diameter) must not be selected for this
procedure [24].
Speciﬁc issues for management of elderly patients with ASD
Again, clinical features of ASD in the elderly are signiﬁcantly
different from those in children and young adults. Elderly patients
with ASD frequently present with hemodynamic abnormalities
such as pulmonary hypertension, atrial arrhythmias, and valvu-
lar regurgitation, which cause congestive heart failure. Moreover,
various comorbidities, such as hypertension, chronic obstructive
pulmonary disease, coronary artery disease, and left ventricular
diastolic dysfunction often complicate the clinical features in this
population. Left ventricular diastolic dysfunction, which is also seen
as part of normal aging and frequently occurs in elderly individuals
with hypertension or increased arterial stiffness, may  cause acute
congestive heart failure after ASD closure [25].
After the introduction of Amplatzer Septal Occluder, tran-
scatheter ASD closure has become a well-established treatment
for secundum-type ASD, with hemodynamically signiﬁcant
left-to-right shunt in children and young adults. Several stud-
ies and our own experience have demonstrated clinical beneﬁts
and positive right-heart remodeling, with reduction of the right
ventricular end-diastolic diameter [26]. However, few studies
were published considering geriatric patients, older than 70 years
[27,28]. In this aged population, not only catheter closure of
ASD but also surgical closure has been reported but with very
T. Akagi / Journal of Cardiology 60 (2012) 151–159 155
Fig. 5. Intracardiac echocardiography (ICE)-guided transcatheter atrial septal defect
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Fig. 6. Catheter closure of multiple atrial septal defects (ASDs). (A) Three-ASD) closure. (A) Short-axis view of phased-array ICE demonstrating the anterosu-
erior rim deﬁciency before closure. (B) Balloon sizing ASD diameter was  22 mm.
C)  ASD was closed with 22 mm device.
imited experience, as few data have been published on functional
esults.
In our institution, transcatheter closure of ASD was  attempted
n 595 patients from 2005 to 2012, among those patients 30 were
ged older than 70 years at the time of catheter intervention and
ollowed up for more than 1 year [11]. The mean age was 75.8 ± 3.8
ears with an age range of 70–85 years. Eighteen of the thirty
atients had been diagnosed with ASD within 2 years before tran-
catheter closure was attempted, but the others well before that.
ost of the patients had at least one major comorbidity, including
ystemic hypertension, stroke, coronary artery disease, and atrial
brillation. Mean systolic pulmonary artery pressure at the time of
iagnostic catheterization was 35.6 ± 11.8 mmHg. Twelve patients
ad been diagnosed with ASD well before transcatheter closure
as attempted but they had refused or hesitated to receive ASD
losure. We  think that this was partially because they had no rec-
gnizable symptoms, but mainly because surgical closure was  the
nly treatment at the time when they had been ﬁrst diagnosed
ith ASD. More than half of the patients were being treated with
 diuretic for congestive heart failure, and 30% of the patients haddimensional transesophageal echocardiography imaging shows isolated 2 defects,
large defect was 24 mm and small defect was 7 mm.  (B) Balloon sizing was performed
simultaneously on both defects. (C) A 28 mm and 10 mm devices were deployed.
a history of hospitalization due to heart failure. Seventeen patients
were classiﬁed as New York Heart Association (NYHA) functional
class II and 8 patients were classiﬁed as class III. Only 5 patients had
no symptoms despite signiﬁcant shunt ﬂow and were classiﬁed as
NYHA functional class I. One patient had two defects. Mean defect
diameter was 20.3 ± 6.4 mm,  and a circumferentially sufﬁcient rim
(>5 mm rim around the defect) was  observed in only 8 patients.
Previous studies have suggested that development of acute con-
gestive heart failure is due to abrupt elevation in left ventricular
preload following transcatheter ASD closure, especially in elderly
156 T. Akagi / Journal of Cardiolo
Fig. 7. Catheter closure of 82-year-old patient with large atrial septal defect (ASD)
and permanent atrial ﬁbrillation. (A) Pulmonary artery wedge pressure (PCWP) was
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artery hypertension, systemic hypertension, and atrial ﬁbrillation,
a high procedural success rate can be expected even in this aged
group. Also, signiﬁcant improvement in NYHA functional class was
observed after closure even though about 30% of the patients in thisontinuously monitored during the device deployment. In this case, intracardiac
chocardiography was  used as imaging guidance. (B) 32 mm device was deployed
nd  no signiﬁcant elevation of PCWP was  observed.
atients with impaired left ventricular systolic or diastolic function
25,29]. In our experience, despite the fact that our patients had
mpaired left ventricular diastolic function estimated by decreased
′ and increased E/e′ as well as various comorbidities such as sys-
emic hypertension, pulmonary artery hypertension, and atrial
brillation, acute congestive heart failure after the ASD closure did
ot develop in any of the patients except in one patient in whom
he procedure was abandoned due to pulmonary artery wedge
ressure (PCWP) elevation during test balloon occlusion. Schubert
t al. reported that peri-procedural anticongestive medication was
ffective in preventing congestive heart failure after ASD closure
n elderly patients [14]. In our experience, 57% of the 30 patients
reviously used oral diuretics, and this high rate of diuretic usage
ight have contributed to prevention of acute congestive heart
ailure after closure.
For patients who had a history of heart failure and were con-
idered to be hemodynamically high-risk, we placed a Swan-Ganzgy 60 (2012) 151–159
catheter into the pulmonary artery from the other femoral vein and
monitored PCWP during the subsequent procedure. And if mean
PCWP increased >10 mmHg  from the baseline value during balloon
occlusion of the defect (test balloon occlusion), or PCWP increased
>20 mmHg, we  judged such ASD closure would lead to pulmonary
edema and the procedure was  abandoned (Fig. 7). Medications such
as diuretics, warfarin, and antihypertension and antiarrhythmia
drugs were continued at the same doses after the procedure.
In our series, prior to ASD closure, test balloon occlusions were
performed in 7 of 30 cases. As a result, the procedure was aban-
doned in one case due to a signiﬁcant elevation of PCWP during test
occlusion of the ASD. This patient was  an 84-year-old thin woman
who had permanent atrial ﬁbrillation, hypertension, chronic kidney
disease, chronic anemia, and severe TR (tricuspid valve regurgita-
tion). She had been repeatedly hospitalized with congestive heart
failure in past years. Her ASD diameter was  24 mm and Qp/Qs was
2.6. During test balloon occlusion, her PCWP immediately increased
from 8 mmHg  to 22 mmHg  and remained at 16 mmHg after 20 min,
thus the procedure was  abandoned. In the other 2 cases, the device
was difﬁcult to deploy because of large size defect. One of those
cases proceeded to surgical closure, and the other case was suc-
cessfully closed in the second attempt of catheter intervention on a
later day. Finally, 28 (93%) of the 30 patients were treated success-
fully by catheter closure. A single device was placed in 27 patients.
In the remaining patient with multiple defects, 2 devices were
deployed at the time of the same procedure. Mean device diam-
eter was 23.3 ± 6.0 mm.  Mean follow-up period was  19.1 ± 11.3
months.
Procedural outcomes of elderly patients with ASD
Fig. 8 shows the procedural and mid-term results. Device clo-
sure was  successfully performed in 28 (93%) of the 30 patients
without acute complications. In the other 2 patients, the proce-
dures were abandoned because of technical issues. While only 8
(27%) of the 30 patients had sufﬁcient rim type ASD, 19 (63%) had
aortic rim deﬁcient type. However, there was not much difference
in our device selection between sufﬁcient rim and aortic rim deﬁ-
cient type. Therefore, we  think that the small percentage of patients
with sufﬁcient rim did not have a great impact on device size selec-
tion in the present study. Although the majority of our patients
were complicated with various comorbidities, such as pulmonaryFig. 8. Improvement in New York Heart Association (NYHA) functional class after
catheter closure of atrial septal defect in patients >70 years old.
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tudy had a history of hospitalization for congestive heart failure.
o patient required additional hospitalization for congestive heart
ailure during the follow-up period. The ﬁrst procedure was  suc-
essful in 27 of 30 cases in which transcatheter ASD closure was
ttempted. On the other hand, the procedure was  abandoned in 3
ases. Two patients died during the follow-up period. One died of
rostatic cancer 20 months after ASD closure. The other patient died
 months after the procedure, due to severe chronic obstructive
ulmonary disease and mild left ventricular dysfunction.
trial arrhythmias in adult patients with ASD
Atrial arrhythmias are the most commonly seen comorbidities
n adult patients with ASD. In our experience, approximately one-
hird of patients aged over 60 years, or half of patients aged over
0 years, are complicated with atrial ﬁbrillations. Previously, we
eported the clinical beneﬁts of catheter closure of ASD in patients
ith permanent atrial ﬁbrillation [30]. Even in patients complicated
ith atrial ﬁbrillation, the resolution of left to right shunt con-
ributes to a signiﬁcant improvement in clinical symptoms of these
atients. Although, strict anticoagulation treatment is required
ven after ASD closure, transcatheter closure of ASD should be con-
idered even in patients with permanent atrial ﬁbrillation without
ge limitation. In patients complicated with symptomatic parox-
smal or persistent atrial ﬁbrillation, catheter ablation such as
ulmonary vein isolation should be indicated prior to the catheterstrated 4.5 mm PDA. (B) Amplatzer duct occluder was advanced to the descending
ce was  placed in stable position and ductus was completely closed.
closure of ASD. In our institution, pulmonary vein isolation is going
to be indicated in patients whose age is younger than 75 years, and
who have symptomatic paroxysmal or persistent atrial arrhyth-
mias and left atrial dimension <50 mm.  Transcatheter ASD closure
is scheduled when sinus rhythm persists >3 months after the abla-
tion. Although the experiences are still limited, the collaborations
between electrophysiological and interventional procedures can
contribute to new therapeutic strategies in patients with ASD and
atrial arrhythmias.
PDA and catheter intervention
Clinical features of adult patients with PDA
In general, the majority of patients with PDA are diagnosed
and treated as neonates or children, unrepaired patients with PDA
are considered a relatively rare situation. However, nowadays,
even adult patients with PDA are not rare. Compared to pediatric
patients, adult PDA patients are usually symptomatic with symp-
toms such as shortness of breath or palpitation, which are caused
by congestive heart failure. In such adult patients, if medical treat-
ment is not enough for resolving heart failure, closure of PDA is
considered as the essential treatment. However, surgical closure
of PDA is not such a simple procedure as in pediatric patients.
Long-term persistent left ventricular volume overload causes atrial
arrhythmias and mitral or aortic valve insufﬁciency. Morphology of
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uctus arteriosus is also different from that in the pediatric popula-
ion. Conical shape of ductus is the most common type in pediatric
atients, however in adults, short and tubular or window shape of
uctus is seen frequently. Such morphological features inﬂuence
he difﬁculty of surgical closure of adult PDA. In fact, the major-
ty of adult patients with PDA required cardiopulmonary bypass
nd mid-sternum thoracotomy. Thus, safe and effective catheter
losure of adult PDA is very important.
Indications for PDA closure in adult patients are the same as in
ediatric patients. Catheterization including descending aortogra-
hy is essential for the accurate morphological and hemodynamic
iagnosis of PDA, the latest 3D computed tomography or mag-
etic resonance imaging is quite valuable for decision making of
herapeutic strategies for interventional procedures.
atheter intervention of PDA
In the past, coil occlusion of PDA was the only available ther-
peutic option for catheter closure of PDA in Japan [31]. A Cook
etachable coil or 0.052 inch Gianturco coil was used for interven-
ional procedures. Although this modality was effective in patients
ith small PDA (usually less than 3 mm),  complete closure of mod-
rate or large PDA was always difﬁcult. Multiple coil implantations
ontributed to procedure success for this condition, however, mul-
iple coil implantation required technical skills and there was  a
igher complication rate, such as coil migration or hemolysis [32].
Recently, Amplatzer Duct Occluder (ADO) was  introduced for
atheter intervention for PDA, contributing to a high success rate
nd low complication rate even in moderate or large PDA [33].
he cylindrical, slightly tapered device has a thin retention disk
 mm larger in diameter than its body to ensure secure position-
ng in the ductal ampulla. Similar to the Amplatzer Septal Occluder,
olyester ﬁbers sewn into the device induce thrombosis and rapid
omplete occlusion (Fig. 9). Various diameters of device are avail-
ble from 4 mm to 12 mm.  ADO is introduced from femoral vein
sing 6 French long sheath. The device can be repositioned and
etrieved until detachment. The device was selected >2 mm larger
han narrowest PDA diameter, thus using this device, PDA up to
0 mm diameter can be closed safely. Compared with coil occlusion,
DO is very effective and a safe procedure even in adult patients
ith short or tubular PDA. Although several studies reported that
emolysis caused by residual shunt can occur after the procedure,
ost of those cases resolved naturally within a few days after the
ntimal proliferation around the device [34].
uture direction of catheter intervention for ACHD
In Europe and North America, there are many other types of
evice for CHD, including devices for ventricular septal defect
35], pulmonary valve [36], covered stent [37], patent foramen
vale [38], etc. Unfortunately, we cannot introduce such devices
n Japan at this moment [39]. However, if these interventional
rocedures can be performed safely, it must be of great beneﬁt
ot only for pediatric patients but also adult patients with CHD.
ey issues for expanding such new interventional procedures are
orroboration between pediatric cardiologists and adult cardiolo-
ists. Pediatric cardiologists have good knowledge of CHD, but not
nough experience of age-related complications such as arrhyth-
ias and hypertension. For safe and effective procedure outcomes
n adult patients with CHD, the optimal management of comor-
idities is very important. In this regard, an adult cardiologist has
o conduct the total therapeutic strategies in these patients. If pos-
ible, the establishment of adult CHD specialists in each institution,
hich involves these interventional procedures, is the most desir-
ble direction for optimal patient care.
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